Premium
Comparative trial of low‐dose adriamycin plus cyclophosphamide with or without additive hormonal therapy in advanced breast cancer
Author(s) -
Lloyd Richard E.,
Jones Stephen E.,
Salmon Sydney E.
Publication year - 1979
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197901)43:1<60::aid-cncr2820430108>3.0.co;2-m
Subject(s) - medicine , cyclophosphamide , chemotherapy , breast cancer , hormonal therapy , metastatic breast cancer , oncology , cancer , population , environmental health
We treated 56 women with advanced metastatic breast cancer who had not received prior chemotherapy in a comparative trial of cytotoxic chemotherapy with low‐dose adriamycin plus cyclophosphamide alone or in combination with the androgenic steroid calusterone. The response rate to chemohormonal therapy (65%) could not be shown to be statistically better than that for chemotherapy alone (53%) for this size patient population. However, the median remission duration (21.5 months) was significantly prolonged over the 11.5‐month remission duration for chemotherapy alone (p = 0.03). The median survival of the chemohormonal therapy group was 23.5 months, whereas that for chemotherapy alone was 13.5 months (p = 0.05). These results indicate that the addition of a potent hormonal agent to effective cytotoxic chemotherapy improves the results of treatment of women with metastatic breast cancer.